128 related articles for article (PubMed ID: 8072739)
1. Carrier-free 131I-meta-iodobenzylguanidine: comparison of production from meta-diazobenzylguanidine and from meta-trimethylsilylbenzylguanidine.
Mairs RJ; Gaze MN; Watson DG; Skellern GG; Constable P; McKellar K; Owens J; Vaidyanathan G; Zalutsky MR
Nucl Med Commun; 1994 Apr; 15(4):268-74. PubMed ID: 8072739
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo studies with no-carrier added radioiodinated MIBG.
Franceschini R; Pecorale A; Chinol M; Calcagni ML; Servidei T; Riccardi R; Troncone L
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):72-7. PubMed ID: 9002755
[TBL] [Abstract][Full Text] [Related]
3. No-carrier-added synthesis of meta-[131I]iodobenzylguanidine.
Vaidyanathan G; Zalutsky MR
Appl Radiat Isot; 1993 Mar; 44(3):621-8. PubMed ID: 8472027
[TBL] [Abstract][Full Text] [Related]
4. Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma.
Mairs RJ; Russell J; Cunningham S; O'Donoghue JA; Gaze MN; Owens J; Vaidyanathan G; Zalutsky MR
Eur J Cancer; 1995; 31A(4):576-81. PubMed ID: 7576972
[TBL] [Abstract][Full Text] [Related]
5. Chemical characterization and comparative cellular effects of meta-iodobenzyl guanidine and benzyl guanidine.
Van den Berg JD; Smets LA; Rutgers M; Grummels A; Fokkens R; Jonkergouw P; van Rooij H
Cancer Chemother Pharmacol; 1997; 40(2):131-7. PubMed ID: 9182834
[TBL] [Abstract][Full Text] [Related]
6. No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation.
Mairs RJ; Cunningham SH; Russell J; Armour A; Owens J; McKellar K; Gaze MN
J Nucl Med; 1995 Jun; 36(6):1088-95. PubMed ID: 7769433
[TBL] [Abstract][Full Text] [Related]
7. 3-[211At]astato-4-fluorobenzylguanidine: a potential therapeutic agent with prolonged retention by neuroblastoma cells.
Vaidyanathan G; Zhao XG; Larsen RH; Zalutsky MR
Br J Cancer; 1997; 76(2):226-33. PubMed ID: 9231923
[TBL] [Abstract][Full Text] [Related]
8. No-carrier-added (4-fluoro-3-[131I]iodobenzyl)guanidine and (3-[211At]astato-4-fluorobenzyl)guanidine.
Vaidyanathan G; Affleck DJ; Zalutsky MR
Bioconjug Chem; 1996; 7(1):102-7. PubMed ID: 8741997
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of carrier-free 131I-meta-iodobenzyl-guanidine by novel routes to enhance therapeutic efficiency in neuroblastoma.
Gaze MN; Mairs RJ; Vaidyanathan G; Zalutsky MR
Prog Clin Biol Res; 1994; 385():347-53. PubMed ID: 7972229
[No Abstract] [Full Text] [Related]
10. Renal excretion of iodine-131 labelled meta-iodobenzylguanidine and metabolites after therapeutic doses in patients suffering from different neural crest-derived tumours.
Wafelman AR; Hoefnagel CA; Maessen HJ; Maes RA; Beijnen JH
Eur J Nucl Med; 1997 May; 24(5):544-52. PubMed ID: 9142736
[TBL] [Abstract][Full Text] [Related]
11. Implications of the uptake of 131I-radiolabelled meta-iodobenzylguanidine (mIBG) for the targeted radiotherapy of neuroblastoma.
O'Donoghue JA; Wheldon TE; Babich JW; Moyes JS; Barrett A; Meller ST
Br J Radiol; 1991 May; 64(761):428-34. PubMed ID: 2036567
[TBL] [Abstract][Full Text] [Related]
12. Meta-[131I]iodobenzylguanidine uptake and meta-[211At]astatobenzylguanidine treatment in human medulloblastoma cell lines.
Strickland DK; Vaidyanathan G; Friedman HS; Zalutsky MR
J Neurooncol; 1995; 25(1):9-17. PubMed ID: 8523094
[TBL] [Abstract][Full Text] [Related]
13. Radiochemical stability during infusion of 131I-labelled metaiodobenzylguanidine for therapeutic use.
Wafelman AR; Hoefnagel CA; Beijnen JH
Nucl Med Commun; 1993 Sep; 14(9):819-22. PubMed ID: 8233249
[TBL] [Abstract][Full Text] [Related]
14. Radiochemical purity, at expiry, and radiochemical stability of iodine-131 labelled meta-iodobenzylguanidine concentrates for intravenous infusion.
Wafelman AR; Hoefnagel CA; Maes RA; Beijnen JH
Nuklearmedizin; 1996 Aug; 35(4):122-5. PubMed ID: 8784866
[TBL] [Abstract][Full Text] [Related]
15. Radiochemical purity of iodine-131 labelled metaiodobenzylguanidine infusion fluids: a report from clinical practice.
Wafelman AR; Suchi R; Hoefnagel CA; Beijnen JH
Eur J Nucl Med; 1993 Jul; 20(7):614-6. PubMed ID: 8370383
[TBL] [Abstract][Full Text] [Related]
16. Total-body scintigraphy with 131I-meta-iodobenzylguanidine for detection of neuroblastoma.
Hoefnagel CA; Voûte PA; de Kraker J; Marcuse HR
Diagn Imaging Clin Med; 1985; 54(1):21-7. PubMed ID: 3918823
[TBL] [Abstract][Full Text] [Related]
17. 131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes.
Gaze MN; Mairs RJ; Boyack SM; Wheldon TE; Barrett A
Br J Cancer; 1992 Dec; 66(6):1048-52. PubMed ID: 1457344
[TBL] [Abstract][Full Text] [Related]
18. Fast high-yield labelling and quality control of [123I]- and [131I]MIBG.
Verbruggen RF
Int J Rad Appl Instrum A; 1987; 38(4):303-4. PubMed ID: 3040631
[No Abstract] [Full Text] [Related]
19. Rapid radiochemical purity testing for [131I]m-iodobenzylguanidine.
Hung JC; Wilson ME
Nucl Med Biol; 1995 Feb; 22(2):227-9. PubMed ID: 7767317
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and treatment of neuroblastoma using 131I-meta-iodobenzylguanidine.
Edeling CJ; Büchler Frederiksen P; Kamper J; Jeppesen P
Nuklearmedizin; 1986 Oct; 25(5):172-5. PubMed ID: 3797256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
